Stocklytics Platform
Asset logo for symbol ATNM
Actinium Pharmaceuticals
Penny Stock
Asset logo for symbol ATNM


Key Stats
Prev. Close$7.38
Next Earnings Date-
Dividend Yield %-
Market Cap$219.80M
PE Ratio-
Day Range7.15
52 Week Range4.00
EBITDA Margin %-
Gross Profit-
Payout Ratio-
Industry average yield2.93%
Last Dividend pay dateAug 11, 2020
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_up1.85%
US Marketarrow_drop_up1.39%
ATNM / Market
ATNM lose to the US Market which returned 1.39% over the last twenty four hours.
ATNM / Healthcare Sector
ATNM lose to the US Healthcare sector which returned 1.85% over the last twenty four hours.

Actinium Pharmaceuticals (ATNM) Statistics

Actinium Pharmaceuticals Inc (ATNM) is a pharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer. The company focuses on targeted therapies that harness the power of radiation to selectively destroy cancer cells while sparing healthy tissue. ATNM utilizes its proprietary technology platform to develop targeted radioimmunotherapies (RITs) and alpha particle immunotherapies for various types of cancer. These therapies have the potential to significantly improve patient outcomes and reduce the side effects associated with traditional cancer treatments.

When it comes to valuation metrics, ATNM stock is currently trading at a price-to-sales ratio of X, which is below the industry average. This suggests that the stock may be undervalued compared to its peers in the pharmaceutical sector. Additionally, ATNM has a market capitalization of $X billion, reflecting the market's perception of the company's future growth potential.

add Actinium Pharmaceuticals  to watchlist

Keep an eye on Actinium Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has Actinium Pharmaceuticals (ATNM) stock's performance compared to its sector and the market over the past year?

Over the past year, Actinium Pharmaceuticals (ATNM) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.13%, Actinium Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.53%, it has fallen short of the market average. This comparison highlights Actinium Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of Actinium Pharmaceuticals (ATNM) stock?

The PE ratio for Actinium Pharmaceuticals (ATNM) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the EPS of Actinium Pharmaceuticals (ATNM) stock?

The Earnings Per Share (EPS) for Actinium Pharmaceuticals (ATNM), calculated on a diluted basis, is -$1.71. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of Actinium Pharmaceuticals (ATNM) stock?

The operating margin for Actinium Pharmaceuticals (ATNM) is -61.65K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Actinium Pharmaceuticals (ATNM) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Actinium Pharmaceuticals (ATNM) is -$49.69M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does Actinium Pharmaceuticals (ATNM) have?

Actinium Pharmaceuticals (ATNM) has a total debt of $1.98M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$82.08M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level